Targeting tumor hypoxia with hypoxia-activated prodrugs.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

18 citing papers in PubMed.

1. Monitoring early response to chemoradiotherapy withEuropean journal of nuclear medicine and molecular imaging · 2017
   Trial
2. TH-302 (evofosfamide) monotherapy exerts anticancer activity in Ewing's sarcoma cells under hypoxia.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
   Article
3. Exploring chronic and transient tumor hypoxia for predicting the efficacy of hypoxia-activated pro-drugs.NPJ systems biology and applications · 2024
   Article
4. Bioactive materials · 2023
   Article
5. Hypoxia-inducible lentiviral gene expression in engineered human macrophages.Journal for immunotherapy of cancer · 2022
   Article
6. Normalizing Tumor Vasculature to Reduce Hypoxia, Enhance Perfusion, and Optimize Therapy Uptake.Cancers · 2021
   Review
7. Evofosfamide Is Effective against Pediatric Aggressive Glioma Cell Lines in Hypoxic Conditions and Potentiates the Effect of Cytotoxic Chemotherapy and Ionizing Radiations.Cancers · 2021
   Article
8. Hypoxia Predicts Poor Prognosis in Neuroblastoma Patients and Associates with Biological Mechanisms Involved in Telomerase Activation and Tumor Microenvironment Reprogramming.Cancers · 2020
   Article
9. Hypoxia Impairs NK Cell Cytotoxicity through SHP-1-Mediated Attenuation of STAT3 and ERK Signaling Pathways.Journal of immunology research · 2020
   Article
10. Micropharmacology: An In Silico Approach for Assessing Drug Efficacy Within a Tumor Tissue.Bulletin of mathematical biology · 2019
    Article
11. Tumor Hypoxia As an Enhancer of Inflammation-Mediated Metastasis: Emerging Therapeutic Strategies.Targeted oncology · 2018
    Review
12. Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment.International journal of nanomedicine · 2018
    Review
13. A bioreducible N-oxide-based probe for photoacoustic imaging of hypoxia.Nature communications · 2017
    Article
14. Emerging targets for radioprotection and radiosensitization in radiotherapy.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Review
15. Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors.PLoS computational biology · 2016
    Article
16. Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinoma.Proceedings of the National Academy of Sciences of the United States of America · 2016
    Article
17. Hypoxia, Epithelial-Mesenchymal Transition, and TET-Mediated Epigenetic Changes.Journal of clinical medicine · 2016
    Review
18. No patient left behind: The promise of immune priming with epigenetic agents.Oncoimmunology
    Review

Corrections and comments

• Comment on
  Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer.2015

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as